Aortic valve sclerosis (AVS) may predispose to a prothrombotic state, as AVS is predictor of cardiovascular events in hypertensive populations. Thrombin exerts non-thrombotic effects such as vessel tone regulation, progression of atherosclerosis and stimulation of atrial natriuretic peptide (ANP) secretion. We hypothesized that hypertensive patients with AVS may have a persistently activated thrombin generation. We studied 234 asymptomatic never-treated hypertensive patients (73 of them with AVS). Prothrombin F1 þ 2 (F1 þ 2), as a marker of thrombin generation and fibrin D-dimer, as a marker of thrombus formation, ANP and brain natriuretic peptide (BNP) were measured. Presence of AVS, aortic jet velocity and left ventricular diameter at diastole were determined by echocardiography. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease formula. F1 þ 2 (median and interquartile range (IQR) ¼ 1.05, 0.87-1.38 nM vs 0.93, 0.72-1.16) and ANP (22, 14-37 pg ml À1 vs 17, 11-25) levels were greater, and glomerular filtration rate values (65 ± 9 ml min À1 /1.73 m 2 vs 68 ± 11) were lower in hypertensive patients with AVS than in those without AVS. F1 þ 2 (odds ratio, 95% CI ¼ 2.94, 1.07-8.6) was independently associated with AVS after being adjusted for age, gender and the variables of cardiorenal functions measured. After 6 months of treatment using valsartan, F1 þ 2 levels remained elevated in hypertensive patients with AVS (1.14, 0.83-1.42 nM vs 1.07, 0.84-1.5, n ¼ 19), but decreased in those without AVS (1.01, 0.85-1.31 vs 0.8, 0.84-1.78, n ¼ 27). Thrombin generation was associated with AVS in untreated hypertensive patients, and this association was persistent after blood-pressure-lowering treatment using valsartan.
Introduction
Aortic valve sclerosis (AVS) was independently associated with cardiovascular events in high-risk hypertension with left ventricular hypertrophy, 1 as well as in the elderly general population, 2 in spite of its haemodynamically nonsignificant valvular lesion. Although the precise mechanism of this adverse outcome is not fully known, 3 it can be speculated that AVS may be associated with a prothrombotic state, leading to subsequent thrombotic events or the progression of atherosclerosis.
A prothrombotic state or a hypercoagulable state can be defined biochemically as heightened activation of blood coagulation with the absence of thrombosis. 4 The prothrombotic state may exist in hypertensive patients with AVS, as AVS has been regarded as a surrogate marker for underlying atherosclerotic diseases, generalized systemic process such as inflammation, 3 and endothelial dysfunction. 5 In addition, hypertensive patients themselves have a predisposition to the prothrombotic state. 6 Thrombin, a multifunctional serine protease, is important not only in blood coagulation, but also in virtually every aspect of vascular biology including regulation of vessel tone, atherogenesis and smooth muscle cell proliferation. 7 These biological properties of thrombin may contribute to various nonthrombotic associations with progression of atherosclerosis and heart diseases. 8 Indeed, plasma levels of prothrombin F1 þ 2 (F1 þ 2) as a marker of thrombin generation have been shown to be elevated in hypertension with target organ damage 9 and in heart failure. 10 Furthermore, thrombin may influence haemodynamic properties of hypertensive patients through atrial natriuretic peptide (ANP), as thrombin stimulates the secretion of ANP from cardiomyocytes, 11 and ANP causes vasodilatation and increase renal excretion of sodium and water. 12 Nevertheless, as far as we know, little is known about the role of thrombin generation in hypertensive patients with AVS.
We hypothesized that hypertensive patients with AVS may have an accelerated and persistent thrombin generation. To test this hypothesis, we measured F1 þ 2, fibrin D-dimer (D-dimer) as a marker of fibrin formation and fibrinolysis, ANP, brain natriuretic peptide (BNP) in asymptomatic never-treated hypertensive patients.
Methods

Study population
We studied 234 consecutive patients with nevertreated hypertension who visited our outpatient clinic during the period from November 1998 to December 2004. Each patient had chronically elevated blood pressure (BP), and was asymptomatic and informed of the presence of hypertension coincidentally at their annual health check or by local general practitioners. Duration of suffering hypertension was usually less than few years at the time of enrolment. Inclusion criteria consisted of the following (1) sitting systolic BP above 140 mm Hg and diastolic BP above 90 mm Hg, (2) no history of cardiovascular disease such as stroke, myocardial infarction, heart failure (3) of sinus rhythm and no complication of serious arrhythmia. We excluded patients if they had malignant disorders or chronic renal failure with serum creatinine level 41.5 mg ml
À1
. Healthy subjects without hypertension, diabetes, hyperlipidaemia or cardiovascular diseases served as controls (n ¼ 54). They were referred for echocardiography during the same enrolment periods because benign electrocardiogram findings such as coincidental supraventricular premature beats, poor R progression or high voltage in chest lead were pointed out in their annual health check up. Their echocardiogram did not reveal significant abnormalities.
We initiated blood-lowering therapy using the angiotensin II receptor blocker valsartan in January 2002 for hypertensive patients. In total, 50 hypertensive patients agreed to be medicated with valsartan. BP was measured at enrolment, then at intervals of 1, 2, 4 and 6 months of anti-hypertensive medication in the sitting position, using sphygmomanometer by experienced nurses. The therapeutic target of BP was set up to be 140/90 mm Hg. If this target BP was not achieved after 1 month's treatment of 80 or 160 mg of valsartan, calcium channel blocker was added to the regimen.
Echocardiography
All the participants underwent transthoracic echocardiography using a commercially available instrument (Sonos 5500, Philips, Best, the Netherlands). Two-dimensional and M-mode measurements were made according to the recommendations of the American Society of Echocardiography. Left ventricular posterior thickness (LVWT) at end diastole, left ventricular diameter at diastole (LVDd) were measured and indexed for body surface area (LVWT/BSA and LVDd/BSA). AVS was defined as thickening of aortic valve leaflets with preserved leaflet mobility. Maximum aortic jet velocity was measured using continuous Doppler echocardiography, and the presence of aortic regurgitation was assessed using colour Doppler echocardiography.
Assessment of biomarkers and estimation of renal function Blood samples were collected on the same day as echocardiography to measure the plasma levels of F1 þ 2, D-dimer, ANP and BNP. F1 þ 2 levels were measured using an enzyme immunoassay (Enzygnost F1 þ 2, Behringwerke, Marburg, Germany). Plasma levels of natriuretic peptides were measured using specific immunoradiometric assays for ANP (Shionoria, Shionogi, Osaka, Japan) and BNP (Shionoria, Shionogi). D-dimer levels were measured using a latex photometric immunoassay (Elpiaace D-D dimer-II, Mitsubish-Kagaku Iatron, Tokyo, Japan). Glomerular filtration rate (GFR) was estimated using 
Statistical analysis
Comparisons between the patients and the control group were determined using unpaired t-test or the Mann-Whitney test as appropriate for continuous variables, and the w 2 -analysis for categorical variables. The intergroup comparisons of pre-treatment and post-treatment values were compared using two-factor analysis of variance for repeated measures or Wilcoxon signed rank test, as appropriate. The distributions of F1 þ 2, D-dimer, ANP and BNP were rightly skewed, so these variables were expressed as median and interquartile range (IQR), and log-transformed for logistic regression analysis. To investigate relationships between F1 þ 2 and ANP, a multiple linear regression model was constructed with log F1 þ 2 as dependent variable and clinical factors (age, gender, estimated GFR, log ANP) as predictors. Association of each haemostatic marker with the presence of AVS was investigated using a multivariate logistic regression model. The JMP version 6.0 (SAS institute, Cary, NC, USA) statistical package was used for data analysis.
Results
Patient characteristics
Clinical characteristics that might influence plasma levels of haemostatic markers did not differ between never-treated hypertensive patients and the control (Table 1) . However, F1 þ 2 and D-dimer levels were significantly were elevated in never-treated hypertensive patients than in the control (Table 1) . Age, gender, serum creatinine level and therefore estimated GFR values were not different between hypertensive patients and control subjects.
Associations of thrombin generation with AVS and natriuretic peptides
Aortic valve sclerosis was recognized in 73 out of 234 never-treated hypertensive patients. Plasma levels of F1 þ 2 and D-dimer were significantly greater in hypertensive patients with AVS than in those without AVS (Table 2) . A multivariate logistic regression analysis revealed that F1 þ 2 (odds ratio, 95% CI ¼ 2.94, 1.07-8.6) was associated with the presence of AVS even after adjusted multivariately for age, gender, log ANP, log BNP, LVDd/BSA, estimated GFR and aortic jet velocity. D-dimer (Table 4) .
Effects of valsartan on thrombin generation
Since January 2002, 50 consecutive patients agreed to receive BP-lowering medication using valsartan. For two patients, the medications were discontinued because of minor adverse effects. Contact was lost with two patients during the follow-up periods. AVS was detected in 19 patients out of the remaining 46 hypertensive patients. Plasma levels of pre-treatment F1 þ 2, D-dimer and BNP were not different between hypertensive patients with AVS and those without AVS. Pre-treatment levels of systolic and diastolic BP, and blood-lowering effects by medications were also similar between the two groups. F1 þ 2 and BNP levels in patients with AVS were not lowered by 6-month treatment with valsartan, whereas those in patients without AVS were significantly decreased. D-dimer levels did not change in the two groups (Table 5 ).
Discussion
The major findings of this study was that thrombin generation, manifested by F1 þ 2 levels, was associated with the presence of AVS in never-treated hypertensive patients, even after being adjusted for age, gender and the other parameters of cardiorenal dysfunctions. F1 þ 2 levels were associated with those of ANP. In addition, plasma levels of F1 þ 2 remained being elevated after 6-month treatment of valsartan, an angiotensin II receptor blocker.
The present study indicated that never-treated hypertensive patients with AVS had greater levels of F1 þ 2 and D-dimer than those without AVS. These results are consistent with previous reports showing that these haemostatic markers are elevated in hypertensive patients with target organ damage. 
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Renal function is an important contributor for determining the plasma levels of haemostatic markers measured, as were shown in the report by Sechi et al. 13 that log F1 þ 2 and log D-dimer were inversely correlated with creatinine clearance in hypertensive patients, indicating the association between impaired renal function and prothrombotic state. In accordance with the report by Sechi et al., the present study revealed that hypertensive patients with AVS had a greater F1 þ 2 level and a lower estimated GFR value than those without AVS. Thus, impaired renal function may be attributable to elevated F1 þ 2 levels in hypertensive patients with AVS. Nevertheless, the presence of CKD, determined by GFR below 60 ml min À1 /1.73 m 2 , did not affect F1 þ 2 levels in hypertensive patients with AVS. Furthermore, even after being adjusted for GFR and other variables of cardiac function, the association between AVS and F1 þ 2 levels remained significant in never-treated hypertensive patients. The relation between AVS and thrombin generation in our study is likely to be independent of cardiorenal dysfunctions.
The present study indicated that D-dimer levels were elevated in never-treated hypertensive patients, but the association of D-dimer with AVS was lost after being adjusted for age, gender and the other variables. These results may be a reflection of our study protocol to exclude patients with overt thrombosis such as ischaemic heart disease and stroke, but may indicate that the prothrombotic state manifested by activated thrombin production with minimum fibrin formation exists even in hypertensive patients of their early stages prior to antihypertensive medication. A hypercoagulable state can be defined biochemically if there is heightened activation of the blood coagulation mechanism in the absence of thrombosis, 4 suggesting that thrombin generation does not necessarily lead to final thrombus formation. Indeed, Biasucci et al.
14 reported that patients with unstable angina developed bursts of thrombin production not necessarily associated with ischaemic episodes.
The mechanism linking AVS and thrombin generation is not clear. It is possible that AVS may be related to the prothrombotic state through underlying pathological conditions such as endothelial dysfunction, inflammation and renin angiotensin system (RAS) activation. Poggianti et al. 5 revealed that AVS was associated with endothelial dysfunction, demonstrated as an impaired flow-mediated dilation of brachial artery. As for chronic inflammation, pathological studies identified that inflammatory cells are the predominant cell type in early lesions of AVS. Results of clinical studies regarding the association of inflammation with AVS were convincing, 15 but not yet confirmatory. 3 A comprehensive study measuring biomarkers of these pathological conditions in patients with AVS will be necessary to shed light on this subject.
Atrial natriuretic peptide may be a possible candidate linking thrombin generation and endothelial dysfunction. ANP is secreted by high BP, and exerts its BP-lowering action through increasing GFR and renal excretion of sodium and water, and causing vasodilation of peripheral vessels. 12 Thrombin, a key enzyme of blood coagulation, is also important in non-thrombotic aspect of vascular biology, such as activating a variety of cell types including platelet and endothelial cells, regulations of vasomotor tone, cell permeability, smooth muscle cell differentiation, leucocyte migration and trafficking. 7, 16 Furthermore, experimental studies revealed that thrombin stimulates ANP secretion and induce hypertrophy 11, 17 of cardiomyocytes, and on the other hand, ANP and BNP attenuate the secretion of endothelin-1 stimulated by thrombin or angiotensin II of cultured human endothelial cells. 18 In line with these experimental findings, the present study indicated that hypertensive patients with AVS had greater levels of F1 þ 2 and ANP than those without AVS. F1 þ 2 levels were associated with ANP levels in all of the hypertensive patients. These findings lead us to speculate that thrombin and ANP may Aortic valve sclerosis and thrombin in hypertension M Iida et al interact with each other in never-treated hypertensive patients with AVS. In our study, F1 þ 2 and BNP levels significantly decreased after 6-month treatment using valsartan in hypertensive patients without AVS. The finding was compatible with a previous study by Felmeden et al. 19 that elevated levels of tissue factor, an initiator of the blood coagulation cascade, and von Willebrand factor were decreased by intensive BP-lowering treatment.
Activation of RAS leads to enhancement of tissue factor expression, sequentially leading to thrombin generation. 20 Experimental studies indicated that inhibition of RAS by angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker resulted in an improvement of fibrinolytic balance or downregulation of tissue factor synthesis. 20 A clinical study by Koh et al. 21 revealed that angiotensin II receptor blockade using candesartan, losartan, irbesartan reduced PAI-1 and tissue factor activity in hypertensive patients.
The mechanism of the inhibitory effect of valsartan on thrombin generation could be attributable to experimental findings that valsartan decreased the expression of tissue factor in angiotensin II induced vasculopathy, 22 and improved impaired fibrinolytic balance in a cholesterol-fed rabbit model. 23 In Addition, valsartan has been recently shown to reduce high-sensitive C-reactive protein levels in hypertensive patients, raising the hypothesis that angiotensin receptor blockade may have anti-inflammatory effects. 24 In contrast, F1 þ 2 and BNP levels did not change after 6 months of treatment with valsartan in hypertensive patients with AVS. Thus, we speculate that patients with AVS may be resistant to the effect of angiotensin II blocking on haemostatic properties, as hypertensive patients with AVS are likely to have a sustained and progressive atherosclerotic burden. A low-grade thrombin generation may be persistent in these clinical settings, contributing to the progression of atherosclerosis and consequently to an adverse outcome. However, it may take a longer term until valsartan exerts a modulatory effect on haemostatic properties particularly in this patient group. Repetitive measurements of the haemostatic markers during a longer-term follow-up period will be required to evaluate this point.
Estimated GFR levels and creatinine levels were not different between all the hypertensive patients and the control in our study. This may be a reflection of the characteristic of hypertensive patients who were enrolled in their relatively early stages with duration of high BP less than few years. In addition, we excluded patients with serum creatinine level above 1.5 mg ml À1 to avoid chronic renal failure.
In conclusion, hypertensive patients with AVS were associated with prothrombotic state in their early stages, and were resistant to an inhibitory effect of angiotensin II blocking on thrombin generation. Screening for the presence of AVS and prothrombotic tendency will benefit the management of hypertensive patients, especially for identifying possible candidates of a related high-risk group.
Study limitation
As our study was of exploratory design, we did not estimate the target number of patients to be recruited. For the effect of valsartan on thrombin generation, although the change of F1 þ 2 levels was statistically significant at P ¼ 0.05 and a power of 0.8, our sample size was relatively small. In addition, the allocation of treatment to AVS patients was not randomized. To confirm the result of this study, a clinical study of larger size to explore the effect of valsartan on F1 þ 2 levels will be necessary. Nevertheless, the present study, as far as we know, is the first report to compare the effect of valsartan on haemostatic properties, according to the presence or absence of AVS in hypertensive patients.
Although F1 þ 2 elevation was persistent in hypertensive patients with AVS, it is not clear whether such elevated levels of F1 þ 2 represent the tail-end of an acute burst of thrombin generation or a persistent low-grade activation of thrombin because of the short half-life of F1 þ 2.
14 However, we carefully excluded patients with both obvious thrombosis and acute illness to avoid the possibility of an acute burst of thrombin generation at the time of blood sampling.
